Companies · Biotechnology

Vestagen Protective Technologies, Inc.

ORLANDO · Biotechnology

Diligence memoA one-page analyst read on Vestagen Protective Technologies, Inc. — recommendation, valuation, rhythm, risks.
$25.5M
Total raised · real
4
Rounds
32.0×
Latest step-up
Top 29%
Sector rank · raised
Series B
Latest stage · inferred · Fri Mar 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Vestagen Protective Technologies, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.80× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era.
  • Within the normal band (80% of peer median) for its niche.
Dormant
  • Last raise 9.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Vestagen Protective Technologies, Inc. is one of 4293 Biotechnology companies tracked from ORLANDO. By capital raised it ranks in the upper tier (ahead of 72% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
8
Investors (latest)
2013
Year incorporated
2017-03-31
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2013-08-02 Raised $5.8M (real) Modeled valuation $208M (est)$5.8M$208MSeries A2013Series A · 2015-09-04 Raised $3.3M (real) Modeled valuation $119M (est)$3.3M$119MSeries A2015Series A · 2017-01-24 Raised $500K (real) Modeled valuation $18M (est)$500K$18MSeries A2017Series B · 2017-03-31 Raised $16M (real) Modeled valuation $635M (est)$16M$635MSeries B2017+$3.3M+$500K+$16MCumulative $26M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.8M · 2013
Series A extension$3.3M · 2015
Series A extension$500K · 2017
Series B$16.0M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$634.6M
Base estimate est.
$32.0M
Conservative case
$2.4B
Upside case
$88.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $207.9M · 2013-08-022013Series A · modeled $119.3M · 2015-09-04Series A · modeled $18.1M · 2017-01-24Series B · modeled $634.6M · 2017-03-312017
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
9.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
15 mo
Avg between rounds
$7.0M/yr
Capital velocity
12.9 yr
On record since
2013
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.5× above median
This company$25.5M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.9× of median
This company$16.0M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 9.9× above median
This company$634.6M
Sector median$64.2M

Raised more than 72% of sector peers (real $). Modeled value above 85% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #65 of 101.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Liquid BioScience, Inc. · Series B Raised $40.0M · modeled $1.6B (est)Amphivena Therapeutics, Inc. · Series B Raised $65.2M · modeled $1.5B (est)Tracon Pharmaceuticals, Inc. · Series B Raised $57.7M · modeled $1.5B (est)Tetra Discovery Partners, Inc. · Series B Raised $40.5M · modeled $1.4B (est)ECM Therapeutics, Inc. · Series B Raised $35.2M · modeled $1.4B (est)Recombinetics, Inc · Series B Raised $54.7M · modeled $1.3B (est)Mersana Therapeutics Inc · Series B Raised $93.7M · modeled $1.3B (est)Atox Bio Inc. · Series B Raised $35.1M · modeled $1.3B (est)Valeritas Holdings Inc. · Series B Raised $58.2M · modeled $1.3B (est)Obsidian Therapeutics, Inc. · Series B Raised $32.4M · modeled $1.3B (est)Cellular Biomedicine Group, Inc. · Series B Raised $40.5M · modeled $1.2B (est)Altor Bioscience Corp · Series B Raised $80.1M · modeled $1.2B (est)Vestagen Protective Technologies, Inc. (this company) Raised $25.5M · modeled $634.6M (est)Vestagen Protective Technologies, Inc.
CompanyStageRaised · realValue · estvs peer med.
Liquid BioScience, Inc.Series B$40.0M$1.6B2.00×
Amphivena Therapeutics, Inc.Series B$65.2M$1.5B1.93×
Tracon Pharmaceuticals, Inc.Series B$57.7M$1.5B1.93×
Tetra Discovery Partners, Inc.Series B$40.5M$1.4B1.79×
ECM Therapeutics, Inc.Series B$35.2M$1.4B1.76×
Recombinetics, IncSeries B$54.7M$1.3B1.68×
Mersana Therapeutics IncSeries B$93.7M$1.3B1.65×
Atox Bio Inc.Series B$35.1M$1.3B1.65×
Valeritas Holdings Inc.Series B$58.2M$1.3B1.65×
Obsidian Therapeutics, Inc.Series B$32.4M$1.3B1.62×
Cellular Biomedicine Group, Inc.Series B$40.5M$1.2B1.53×
Altor Bioscience CorpSeries B$80.1M$1.2B1.52×
Vestagen Protective Technologies, Inc. this companySeries B$25.5M$634.6M0.80×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.8M2013-08-02$26.1M$207.9M85%
Series A$3.3M2015-09-04$15.0M$119.3M85%
Series A$500K2017-01-24$2.3M$18.1M90%
Series B$16.0M2017-03-31$88.8M$634.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.8M2013-08-02
    • First recorded raise — entered as Series A.
    • 6 investors on this round.
  2. Series A$3.3M2015-09-04
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 7 investors on this round.
  3. Series A$500K2017-01-24
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 6.6× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  4. Series B$16.0M2017-03-31
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 32.0× larger than the prior — scaling up.
    • 8 investors on this round.
Intelligence
2018 ~Q2
Modeled next raise · ~15mo cadence
$48.0M
Modeled next size est.range $31.2M$76.7M
32.0×
Last step-up
$7.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Dale Benjamin Pfost2017-01
Dale M. Pfost2017-03
Dale P. Pfost2013-08
David Benjamin Nash2017-01
David M. Nash2017-03
David P Nash2015-09
James Benjamin Karides2017-01
James M. Karides2017-03
James P. Karides2013-08
Joe P. Meyernik2013-08
Randy Benjamin Scott2017-01
Randy M. Scott2017-03
Randy P Scott2015-09
Rick P Ferreira2015-09
Uncas Benjamin Favret, III2013-08
William M. Bold2017-01
Registry & provenance

Vestagen Protective Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1584606
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Rion LLCBiotechnologySeries B$25.4M$694.3Msame sector · same stage
FirstLight Bio, Inc.BiotechnologySeries B$25.4M$475.6Msame sector · same stage
1910 Genetics Inc.BiotechnologySeries B$25.7M$795.9Msame sector · same stage
Forte Biosciences, Inc.BiotechnologySeries B$25.2M$771.4Msame sector · same stage
Syntimmune, Inc.BiotechnologySeries B$26.0M$714.4Msame sector · same stage
Perry Health, Inc.BiotechnologySeries B$26.0M$416.6Msame sector · same stage
Gloucester Pharmaceuticals IncBiotechnologySeries B$26.0M$806.7Msame sector · same stage
PostEra Inc.BiotechnologySeries B$26.1M$543.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
ArmaGen, Inc.BiotechnologySeries A$361.5M87%
Milagen, Inc.BiotechnologySeed$146.5M86%
Codagenix Inc.BiotechnologySeries B$323.7M86%
Tangen Biosciences, Inc.BiotechnologySeries A$4.2M86%
Otologic Technologies, Inc.BiotechnologyPre-Seed$1.1M86%
Trait Biosciences Inc.BiotechnologySeries A$28.5M86%
Pillar Biosciences, Inc.BiotechnologySeries B$715.6M85%
Resilient Biotics, Inc.BiotechnologySeries A$50.1M85%
Frequently asked
How much funding has Vestagen Protective Technologies, Inc. raised?
Vestagen Protective Technologies, Inc. has raised approximately $25.5M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Vestagen Protective Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for Vestagen Protective Technologies, Inc. is approximately $634.6M (modeled range $32.0M–$2.4B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Vestagen Protective Technologies, Inc. at?
Vestagen Protective Technologies, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Mar 31.
What does Vestagen Protective Technologies, Inc. do and where is it based?
Vestagen Protective Technologies, Inc. operates in the Biotechnology sector, based in ORLANDO.
Explore related

See where Vestagen Protective Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Vestagen Protective Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.